Actinogen Medical Limited (ATGGF)

OTCMKTS · Delayed Price · Currency is USD
0.0250
+0.0010 (4.17%)
Sep 12, 2025, 12:39 PM EDT
4.17%
Market Cap56.89M
Revenue (ttm)3.60M
Net Income (ttm)-9.66M
Shares Outn/a
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume37,500
Average Volume4,875
Open0.0250
Previous Close0.0240
Day's Range0.0250 - 0.0250
52-Week Range0.0100 - 0.0300
Beta1.06
RSI54.51
Earnings DateAug 28, 2025

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol ATGGF
Full Company Profile

Financial Performance

In 2025, Actinogen Medical's revenue was 5.49 million, a decrease of -44.73% compared to the previous year's 9.93 million. Losses were -14.73 million, 12.9% more than in 2024.

Financial numbers in AUD Financial Statements

News

Actinogen provides pivotal Alzheimer's trial enrolment update and other business news

SYDNEY, April 30, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that its Alzheimer's disease phase 2b/3 trial has now enrolled 60 participants and expects to reach 100 by the...

4 months ago - Benzinga